SCYNEXIS Valuation

Is SCYX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SCYX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SCYX ($1.32) is trading below our estimate of fair value ($56.31)

Significantly Below Fair Value: SCYX is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SCYX?

Other financial metrics that can be useful for relative valuation.

SCYX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does SCYX's PS Ratio compare to its peers?

The above table shows the PS ratio for SCYX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average24.3x
IRD Opus Genetics
2.2x58.8%US$37.1m
PVCT Provectus Biopharmaceuticals
66.3xn/aUS$43.4m
IGC IGC Pharma
26.8x12.8%US$29.1m
ETST Earth Science Tech
2xn/aUS$43.9m
SCYX SCYNEXIS
5.2x29.4%US$50.5m

Price-To-Sales vs Peers: SCYX is good value based on its Price-To-Sales Ratio (5.2x) compared to the peer average (24.3x).


Price to Earnings Ratio vs Industry

How does SCYX's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.7%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.7%
n/an/an/a
No more companies

Price-To-Sales vs Industry: SCYX is expensive based on its Price-To-Sales Ratio (5.2x) compared to the US Pharmaceuticals industry average (2.8x).


Price to Sales Ratio vs Fair Ratio

What is SCYX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SCYX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.2x
Fair PS Ratio1.7x

Price-To-Sales vs Fair Ratio: SCYX is expensive based on its Price-To-Sales Ratio (5.2x) compared to the estimated Fair Price-To-Sales Ratio (1.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SCYX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.32
US$6.67
+405.1%
14.1%US$8.00US$6.00n/a3
Oct ’25US$1.43
US$6.67
+366.2%
14.1%US$8.00US$6.00n/a3
Sep ’25US$1.46
US$6.88
+370.9%
13.0%US$8.00US$6.00n/a4
Aug ’25US$2.04
US$6.88
+237.0%
13.0%US$8.00US$6.00n/a4
Jul ’25US$1.95
US$6.88
+252.6%
13.0%US$8.00US$6.00n/a4
Jun ’25US$2.42
US$6.88
+184.7%
13.0%US$8.00US$6.00n/a4
May ’25US$1.72
US$6.88
+299.7%
13.0%US$8.00US$6.00n/a4
Apr ’25US$1.49
US$6.88
+361.4%
13.0%US$8.00US$6.00n/a4
Mar ’25US$1.62
US$7.13
+339.8%
10.4%US$8.00US$6.00n/a4
Feb ’25US$2.11
US$7.13
+237.7%
10.4%US$8.00US$6.00n/a4
Jan ’25US$2.23
US$8.13
+264.3%
14.0%US$10.00US$7.00n/a4
Dec ’24US$1.72
US$8.13
+372.4%
14.0%US$10.00US$7.00n/a4
Nov ’24US$1.78
US$9.90
+456.2%
27.2%US$15.00US$7.50US$1.345
Oct ’24US$2.28
US$9.90
+334.2%
27.2%US$15.00US$7.50US$1.435
Sep ’24US$3.65
US$11.80
+223.7%
22.4%US$15.00US$9.00US$1.465
Aug ’24US$2.92
US$11.40
+290.4%
26.4%US$15.00US$8.00US$2.045
Jul ’24US$2.95
US$11.40
+286.4%
26.4%US$15.00US$8.00US$1.955
Jun ’24US$2.62
US$11.40
+335.1%
26.4%US$15.00US$8.00US$2.425
May ’24US$3.10
US$11.40
+267.7%
26.4%US$15.00US$8.00US$1.725
Apr ’24US$3.00
US$11.20
+273.3%
28.5%US$15.00US$8.00US$1.495
Mar ’24US$1.73
US$10.60
+512.7%
34.1%US$15.00US$7.00US$1.625
Feb ’24US$1.71
US$15.00
+777.2%
54.8%US$30.00US$7.00US$2.115
Jan ’24US$1.56
US$15.00
+861.5%
54.8%US$30.00US$7.00US$2.235
Dec ’23US$2.12
US$15.00
+607.5%
54.8%US$30.00US$7.00US$1.725
Nov ’23US$2.23
US$18.00
+707.2%
56.5%US$30.00US$7.00US$1.785

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies